MSN

MSN India was established in 2003 and has a history of 20 years. As one of the fastest growing research-based pharmaceutical companies in India, its turnover has achieved from $22 million in 2005 to approximately $670 million in the 2020-2021 financial year. At present, it has 9 API plants and 5 preparation plants, producing 450+ apis and 300+ finished products, 14,000 employees worldwide, and more than 11,000 R&D personnels.
MSN’s business covers 65 countries and regions, covering 35 therapeutic areas, and has successfully passed the US FDA audit for seven consecutive times..
The total number of patent applications in India and internationally reached 836. In the active DMF filing, it ranks first in the world: 425 in the United States, 118 in the European Union, 72 in South Korea, 58 in Russia, 86 in Canada, 11 in Japan and 62 in China.

Advantage products:

Product Name	Category	Characteristic & Application	CDMF status
Ezetimibe			A
Oseltamivir phosphate			A
Dabigatran etexilate mesylate			I
Riociguat			I
Baloxavir Marboxil			Plan to declare

Back List